Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...

Full description

Bibliographic Details
Main Authors: Thais Rodrigues Macedo, Genilson Fernandes de Queiroz, Thaís Andrade Costa Casagrande, Pâmela Almeida Alexandre, Paulo Eduardo Brandão, Heidge Fukumasu, Samanta Rios Melo, Maria Lucia Zaidan Dagli, Ana Carolina B. C. Fonseca Pinto, Julia Maria Matera
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cells
Subjects:
c-KIT
imatinib mesylate
immunohistochemistry
mast cell tumor
prednisone
vinblastine
Online Access:https://www.mdpi.com/2073-4409/11/3/571

Internet

https://www.mdpi.com/2073-4409/11/3/571

Similar Items